Tresiba FDA Approval History
FDA Approved: Yes (First approved September 25, 2015)
Brand name: Tresiba
Generic name: insulin degludec
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 1, Diabetes, Type 2
Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients one year of age and older with diabetes mellitus.
Development timeline for Tresiba
| Date | Article |
|---|---|
| Dec 19, 2016 | Approval Novo Nordisk Receives FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents With Diabetes |
| Sep 25, 2015 | Approval FDA Approves Tresiba (insulin degludec) for Diabetes Mellitus |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
